UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
May 14, 2010
Date of Report (Date of earliest event reported)
PRO-PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| NEVADA | 000-32877 | 04-3562325 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
7 WELLS AVENUE
NEWTON, MASSACHUSETTS
02459
(Address of principal executive offices) (Zip Code)
(617) 559-0033
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
In order to correct an inadvertent omission, Caturano and Company, P.C. has amended its Consent of Independent Registered Public Accounting Firm, which is Exhibit 23.1 to the Form 10-K Annual Report of Pro-Pharmaceuticals, Inc. (the “Company”) for the 2009 fiscal year filed on March 12, 2010, so as to add a reference to the Company’s Form S-8 Registration Statement no. 333-159247. The amended consent is attached to this report as Exhibit 23.1.
| Item 9.01 | Financial Statements and Exhibits. |
(a) Financial statements of businesses acquired.
Not applicable.
(b) Pro forma financial information.
Not applicable
(c) Shell company transactions.
Not applicable.
(d) Exhibits.
| Exhibit No. |
Description | |
| 23.1 | Consent of Caturano and Company, P.C., dated March 12, 2010 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PRO-PHARMACEUTICALS, INC. | ||
| By: | /s/ ANTHONY D. SQUEGLIA | |
| Anthony D. Squeglia | ||
| Chief Financial Officer | ||
Date: May 14, 2009
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 23.1 | Consent of Caturano and Company, P.C., dated March 12, 2010 | |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-116629, 333-109893 and 333-159247 on Form S-8 of our report dated March 12, 2010 (which report expresses an unqualified opinion and includes explanatory paragraphs relating to the substantial doubt about the Company’s ability to continue as a going concern as discussed in Note 1 and the change in the manner in which the Company accounts for certain warrants as discussed in Note 8), appearing in this Annual Report on Form 10-K of Pro-Pharmaceuticals, Inc. for the year ended December 31, 2009.
/s/ Caturano and Company, P.C.
Boston, Massachusetts
March 12, 2010